Krane Funds Advisors LLC Has $583,000 Stake in Pfizer Inc. (NYSE:PFE)

Krane Funds Advisors LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 6.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,241 shares of the biopharmaceutical company’s stock after buying an additional 1,163 shares during the quarter. Krane Funds Advisors LLC’s holdings in Pfizer were worth $583,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. GoalVest Advisory LLC boosted its holdings in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in Pfizer in the fourth quarter worth $36,000. DiNuzzo Private Wealth Inc. bought a new stake in Pfizer in the fourth quarter valued at $37,000. Finally, Life Planning Partners Inc acquired a new position in shares of Pfizer during the fourth quarter valued at about $39,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.4 %

Shares of Pfizer stock traded down $0.12 during mid-day trading on Friday, hitting $27.53. 29,461,921 shares of the stock were exchanged, compared to its average volume of 32,712,070. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a 50-day simple moving average of $27.56 and a 200 day simple moving average of $27.78. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.36.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period last year, the company posted $1.23 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.10%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.